IBI3002

DRUG5 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., The First Affiliated Hospital of Soochow University

Conditions

AsthmaAtopic DermatitisHealthy Participants

Phase 1

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

CompletedNCT06213844

Innovent Biologics (Suzhou) Co. Ltd.Asthma, Healthy Participants

Start: 2024-02-26End: 2025-09-11Updated: 2025-11-21

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

CompletedNCT06947408

Innovent Biologics (Suzhou) Co. Ltd.Asthma

Start: 2025-05-14End: 2026-05-11Updated: 2026-06-09

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

RecruitingNCT07015762

The First Affiliated Hospital of Soochow UniversityAtopic Dermatitis

Start: 2025-07-14End: 2026-05-20Target: 9Updated: 2025-08-07

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma

RecruitingNCT07015749

The First Affiliated Hospital of Soochow UniversityAsthma

Start: 2025-06-20End: 2026-05-20Target: 12Updated: 2025-11-19

Phase 2

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

RecruitingNCT07399067

Innovent Biologics (Suzhou) Co. Ltd.Atopic Dermatitis

Start: 2026-02-06End: 2027-05-27Target: 120Updated: 2026-02-13